Demographics | |
Patients | 105 |
Male | 66 (63) |
Age at lung transplantation years | 31.4 (20.5–43.5) |
Patients <18 years | 18 (17) |
Never-smoker | 88 (84) |
FEV1 % pred | 18 (15–21) |
FVC % pred | 35 (25–48) |
TLC % pred# | 103 (74–119) |
Restrictive GvHD phenotype | 51 (49) |
Airway colonisation | 39 (37) |
Pseudomonas aeruginosa | 20 (19) |
Aspergillus fumigatus | 8 (8) |
eGFR (CKD-EPI) mL·min−1·1.73 m−2 | 93.1 (84.5–119.3) |
SCT | |
Indication | |
Acute myeloid leukaemia | 38 (36) |
Acute lymphoblastic leukaemia | 16 (15) |
Chronic myeloid leukaemia | 18 (17) |
Chronic lymphocytic leukaemia | 2 (2) |
Non-Hodgkin lymphoma | 6 (6) |
Hodgkin lymphoma | 6 (6) |
Myelodysplastic syndrome | 7 (7) |
Nonmalignant disease | 12 (11) |
Type | |
Bone marrow | 51 (49) |
Peripheral blood | 54 (51) |
Age at first SCT years | 22.7 (14.4–36.3) |
>1 SCT attempt | 6 (6) |
Timing of SCT after diagnosis months | 11.2 (4.5–21.0) |
Conditioning treatment | |
Reduced intensity | 16 (18) |
Myeloablative | 87 (83) |
Busulphan | 32 (35) |
Cyclophosphamide | 47 (52) |
Fludarabine | 20 (22) |
Melphalan | 17 (19) |
Total body irradiation¶ | 46 (53) |
GvHD | |
Involvement of any extrapulmonary site | 74 (70) |
Skin | 52 (49) |
Gastrointestinal | 31 (30) |
Ocular | 33 (31) |
Mucosal | 43 (41) |
Extrapulmonary sites n | 2 (0–3) |
Treatment | |
Cyclosporine | 75 (71) |
Steroid | 68 (65) |
Mycophenolate | 31 (30) |
Methotrexate | 18 (17) |
GvHD treatments at lung transplantation n | 2 (2–3) |
Lung transplantation | |
Bilateral lung transplantation | 89 (85) |
Timing of lung transplantation after SCT months | 69 (36–122) |
Lung transplantation <2 years post-SCT | 15 (14) |
Induction | 35 (33) |
Inpatient | 38 (36) |
Intensive care | 23 (22) |
Mechanical ventilation only | 14 (13) |
ECMO only | 5 (5) |
Combined mechanical ventilation and ECMO | 4 (4) |
Inpatient stay post-lung transplantation days | 37 (23–71) |
Patient follow-up post-lung transplantation months | 34 (9–75) |
Data are presented as n, n (%) or median (interquartile range). FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLC: total lung capacity; GvHD: graft versus host disease; eGFR (CKD-EPI): estimated glomerular filtration rate (calculated using the Chronic Kidney Disease Epidemiology Collaboration (2012) formula [22]); ECMO: extracorporeal membrane oxygenation. #: n=91 patients; ¶: n=86 patients.